tbuckley/cabot-search huggingface dataset:
AB0656 Serum vitamin d and parathyroid hormone levels in premenopausal women with fibromyalgia syndrome
Authors: A. Balkarli, H. Balkarlı, S. Temel, N. Ozhan, U. Ozkan, V. Cobankara
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Fibromyalgia syndrome (FMS) is a common chronic musculoskeletal disorder characterized by the presence of widespread pain and multiple tender points on physical examination. Deficiency of vitamin D can cause similar musculoskeletal symptoms. Studies regarding vitamin D and FMS relationship have been done in the recent years. Although some studies determined this relationship, other have failed to do so. <h3>Objectives</h3> We aimed to evaluate the relationship between serum vitamin D and parathyroid hormone (PTH) levels and clinical findings in premenopausal FMS patients. <h3>Methods</h3> 77 patients diagnosed with FMS according to new criteria and 60 healthy women were included in this study. We did not include smokers and obese patients. Both groups were questioned for age, height, weight, BMI, education level, working status, number of children, menarche age, living condition (urban, rural), dressing style and sun exposure. Both groups were checked for serum calcium, phosphor, alkaline phosphatase, vitamin D, and PTH levels. FMS new diagnosis criteria scoring, sleep symptom scale, SF-36, Beck depression scale, BASDAI, VAS, revised fibromyalgia impact (FIQR) questionnaires were done to the patient group, and scores were recorded. Serum vitamin D deficiency was described as ≤20 ng/mL, insufficient vitamin D as 21-29 ng/mL and adequate vitamin D as ≥30 ng/mL. <h3>Results</h3> Mean age was 38,68±5,196 and 38,12±4.939 years for patient and control group, respectively. No significant difference was found between the groups for age, height, weight, BMI, education level, working status, number of children, menarche age, living condition (urban, rural), dressing style and sun exposure (p&gt;0.05). Hemoglobin, calcium, phosphor, and alkaline phosphatase were similar in both groups. Serum vitamin D levels were found lower in the patient group when compared with controls (p=0.000). Parathyroid hormone levels were significantly higher in the patient group (p=0.000). Vitamin D levels were ≤20 ng/mL for 32 (42.7%), 21-29 ng/mL for 14 (18.7%) and &gt;30 ng/mL for 29 (38.7) patients. No significant difference between scores were found when patients who had serum vitamin D levels ≤20 ng/mL and &gt;20 ng/mL compared. SF-36, new diagnosis criteria score and FIQR scores were correlated. Patient serum PTH levels and serum vitamin D levels showed negative correlation, and it was significantly higher than in the control group (p=0.000). <h3>Conclusions</h3> We determined an increase in vitamin D deficiency and insufficiency in FMS patients. However, pain and quality of life scores did now show any significant difference when patient who had vitamin D deficiency and patients who did not have were compared. We highly think that receptor inactivity must be investigated before stating that vitamin D levels and FMS disease scores do not show any correlation. <h3>Disclosure of Interest</h3> None Declared
Clinical Trials: Insurers Defend Coverage Practices
Authors: Cori Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Clinical Trials: Insurers Defend Coverage Practices Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 8, 19 April 1989, Pages 558–559, https://doi.org/10.1093/jnci/81.8.558 Published: 03 January 1990
PWE-170 An Audit Of Clinical Response In Patients With Ibs Treated With The Low Fodmap Diet At St Mary’s Hospital
Authors: V Mcgeoch, V Blackwell, L Wigham, JM Hoare
Journal: Gut (2014)

<h3>Introduction</h3> The low FODMAP diet is a diet used in patients with Irritable Bowel Syndrome. The diet is based on evidence that fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) contribute to symptoms many people experience in Irritable Bowel Syndrome (IBS), including: bloating, flatulence and diarrhoea.<sup>1</sup> This may be due to their fermentation by bacteria and osmotic effects on the bowel.<sup>2 </sup>The low FODMAP diet aims to reduce these carbohydrates and so reduce symptoms. <h3>Methods</h3> The study included all patients treated with the low FODMAP diet at St Marys Hospital between November 2009 and February 2013. Patients treated with the low FODMAP diet were identified using dietetic records and correspondence. Of the whole study population (n = 80), 27 did not attend a follow up appointment and 7 were waiting for follow up at the time of the study. This left 46 patients with follow up appointment data. Their records were analysed and symptom data recorded. A comparison between before and after the diet was then made for symptom changes. <h3>Results</h3> Following treatment with the low FODMAP diet patients reported a lower incidence of each IBS symptom. When the group was assessed for improvement, the results showed that for each symptom, at least 70% of patients improved. The biggest improvements were for bloating (93% improved) and flatulence (92% improved). Average stool consistency reduced from 5.21 to 4.16 on the Bristol Stool Chart. Average stool frequency per day reduced from 3.87 to 1.56. The diet has been used increasingly each year since 2009. <h3>Conclusion</h3> The majority of patients treated with the low FODMAP diet at St Marys Hospital had symptomatic improvements. In this population it has been effective in treating symptoms that are difficult to treat medically such as; bloating, abdominal pain and flatulence. <h3>References</h3> 1 Gibson PR,. <i>et al</i>, Food choice as a key management strategy for functional gastrointestinal symptoms. <i>Am J Gastroenterol</i> 2012 May;107(5):657–66 2 Barrett JS, <i>et al</i>, Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon, <i>Aliment Pharmacol Ther</i> 2010 Apr;31(8):874–882 <h3>Disclosure of Interest</h3> None Declared.
Abstract 2389: Efficacy of ABT-737 against c-Myc-induced mammary adenocarcinomas in transgenic and syngrafted mouse tumor models
Authors: Vilja Eskelinen, Sirkku T. Saarikoski, Anni I. Nieminen, Elias Haapakorva, Elsa Marques, Juha Klefström
Journal: Cancer Research (2011)

Abstract Traditional preclinical discovery methods and models only poorly predict drug efficacy in clinical trials. It has been reasoned that present cultured tumor cell line and xenotransplantation-based in vivo models are too reductionist, failing to recapitulate tumour heterogeneity, tumor-microenvironment interactions and tumor microevolutionary trajectories. The genetically engineered mouse models (GEMMs) hold promise as next generation preclinical models, but the caveat is that GEMMs are not straightforward suitable for preclinical cohort studies. Here we hypothesized that mammary tumors from tumor-prone WAP-Myc mice retain their molecular characteristics and authentic drug responses when recreated as syngrafts in the mammary fat pads of recipient mouse. This platform would allow rapid and non-laborious pilot cohort studies with GEMM tumors. We are testing the hypothesis by determining tumor markers and apoptotic efficacy of BH3-mimetic ABT-737 against c-Myc-induced mammary adenocarcinomas and pulmonary metastases in both transgenic and syngraft models. In the WAP-Myc mice c-Myc is induced in the luminal mammary epithelial cells during late pregnancy resulting in development of endogeneous mammary adenocarcinomas in nearly 100% of multiparous animals. We observe that the tumors are transplantable as cells suspensions (25 000 cells/gland) with approximately 90% success rate. While the transgenic WAP-Myc tumors develop with an average of 3.5 months latency, the syngrafted tumors develop within 3-4 weeks post-transplantation. However, in contrast to 20% rate of pulmonary metastases in the transgenic WAP-Myc mice, syngrafted animals need to be sacrificed prior to metastasis formation. Our preliminary results suggest that the tumor histopathology does not significantly change and the tumor heterogeneity is preserved in the syngrafted tumors. To investigate the response of tumors to ABT-737, animals bearing either endogenous or transplanted tumors were treated with 100mg/kg of ABT-737 for 21 days. ABT-737 reduced primary tumor growth and lung metastases as well as enhanced caspase-3 activity in the transgenic WAP-Myc tumors. Also the syngrafted tumors respond to ABT-737 and the data comparing effects in transgenic versus syngrafted tumors will be presented. Our results demonstrating feasibility of the syngraft platform may help to alleviate many shortcomings of GEMMs in preclinical studies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2389. doi:10.1158/1538-7445.AM2011-2389
Abdominal pain and jaundice after colonoscopy
Authors: C. Snauwaert, L. Vandeputte, M. Cabooter, V. De Wilde, P. Laukens, H. Orlent
Journal: Endoscopy (2013)

An 82-year-old man underwent colonoscopy 6 months after open low anterior resection for an occlusive rectal carcinoma. The colorectal anastomosis appeared normal, and no metachronic polyps were detected. The patient developed abdominal pain and jaundice 2 days after colonoscopy. An abdominal computed tomography (CT) scan showed free fluid in the gallbladder fossa that extended into the hepatorenal recess, suggestive of a bile leak ([Fig. 1]). Endoscopic retrograde cholangiopancreatography (ERCP) confirmed a leak at the insertion of the cystic duct into the common bile duct (CBD; [Fig. 2]); the leak was managed by sphincterotomy and plastic biliary stenting.
Antitumoral Activity of 3rd Generation Derivative Lobaplatin in In Vitro Models of Triple-Negative Breast Cancers.
Authors: A. Honig, T. Martens, S. Häusler, S. Buchholz, B. Rack, J. Wishhusen, J. Dietl, J. Engel
Journal: Cancer Research (2009)

Abstract Introduction:Triple-negative breast cancers are characterized by aggressive growth and early metastasic spread. Some preliminary clinical data have demonstrated good anti-tumor activity of platinum derivatives. 3rd generation compound Lobaplatin* has shown a favorable toxicity profile as compared to Cisplatin. We therefore evaluated this compound in in vitro models of triple negative breast cancers.Study design:Triple-negative humane breast cancer cell lines HCC 1937 and HCC 1806 were treated with increasing concentrations of Lobaplatin and Cisplatin (0,16-10 μm). Cells were incubated for 24, 48 and 72 h with both substances in serum-free and serum-containing medium, in order to evaluate cytotoxic effects in proliferating as well as in metabolically inactive cells. Induction of apoptosis was tested by cleavage of PARP and Caspase 3 as demonstrated by western blot analysis. Subsequently cells were coincubated with Lobaplatin and multi-caspase inhibitor ZVAD-fmk, in order to check if cell death induced by Lobaplatin can be abrogated by inhibition of classical apoptosis. Cytotoxic effects were evaluated by crystal-violet assay. To investigate in which phase of the cell cycle cytotoxicity is most pronounced, cell cycle FACS analysis was performed after treatment with various concentrations of Lobaplatin.Results:Lobaplatin showed a somewhat better anti-tumor activity in both cell lines than Cisplatin. Lobaplatin Induced cleavage of PARP and procaspase 3 indicative for induction of classical apoptosis. However, cytotoxic effects of Lobaplatin were not decreased by multi-caspase inhibitor ZVAD-fmk. Cell-cycle FACS analysis showed, that sub-G0/1 fraction (indicactive for apoptotic/necrotic cells) was increased and G2 fraction was decreased dose-dependently by treatment with Lobaplatin.Conclusion:Lobaplatin showed a good anti-tumor activity in in vitro models of triple negative breast cancers which was at least equal to Cisplatin. Main mechanism of ytotoxicity was programmed cell death, which could not be abrogated by multi-caspase inhibition. Due to the good anti-tumor activity and the favorable toxicity profile, Lobaplatin should be considered for clinical studies in triple negative breast cancers.*Aeterna/Zentaris GmbH, Frankfurt/M Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6115.
On Death and Money
Authors: Angus Deaton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FDG-PET Images of Acrometastases
Authors: Masamichi Koyama, Mitsuru Koizumi
Journal: Clinical Nuclear Medicine (2014)

Skeletal metastasis is common in patients with malignancy, but very few patients have acrometastasis, that is, metastasis to the hand or foot. We present 2 cases of acrometastasis from lung cancer where primary and metastatic foci were demonstrated on FDG-PET. The first case involves a 53-year-old man who complained of left foot pain and had osteolytic metastasis in the left calcaneus due to lung adenocarcinoma. True whole-body PET demonstrated lung cancer with calcaneal metastasis. Another case involves a 62-year-old man with large cell carcinoma of the right lung who complained of right wrist pain. Osteolytic metastasis of the hamate was demonstrated on images.
New Antiepileptic Drugs
Authors: Marc A. Dichter, Martin J. Brodie
Journal: New England Journal of Medicine (1996)

In the past two years, three new antiepileptic drugs — gabapentin, lamotrigine, and felbamate — have been approved for use in the United States. They are the first such drugs to be approved since valproic acid, in 1978. These three drugs and others now in use in Europe, Canada, or Japan or being tested in trials in the United States reflect the resurgence of interest in developing new drugs for the treatment of epilepsy. This article reviews the pharmacologic characteristics of these new drugs, indications for their use, side effects, and appropriate regimens.In many patients with epilepsy, seizures can . . .
Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .
Authors: Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot, Helene Sicard
Journal: Cancer Research (2013)

Abstract KIR3DL2 belongs to the killer immunoglobulin (Ig)-like receptors (KIRs) family and is composed of three extracellular Ig-like domains. KIR3DL2 is naturally expressed on some NK cells and minor subpopulations of CD8+ and CD4+ T cells. Physiologically, KIRD3L2 is an inhibitory receptor for human leukocyte antigen (HLA) class I molecules regulating NK cell activation. Remarkably, KIR3DL2 is also aberrantly overexpressed on several subtypes of T lymphomas/leukemias, such as Sezary Syndrome, transformed Mycosis Fungoides and HTLV1+ Adult T Cell Leukemia, making it a unique therapeutic target in cancer. We have generated a series of anti-KIR3DL2 monoclonal antibodies (mAbs) binding selectively to KIR3DL2, spanning epitopes on each of the three Ig domains. Their efficacy was evaluated in vitro and in vivo against KIR3DL2-expressing tumors and Sezary cell lines as disease model. Various modes of action, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) were found involved in their anti-tumor activity. In parallel, anti-KIR3DL2 mAbs were also developed as unique and sensitive tools for the detection by immunohistochemistry of KIR3DL2 on tumor biopsies. Owing to the promising efficacy profile of our anti-KIR3DL2 mAb candidates and to the highly restricted expression pattern of the target on some T leukemia/lymphoma cells, an antibody-based therapy targeting KIR3DL2 stands as a potentially unequalled strategy in several orphan diseases with critical unmet medical need. Citation Format: Nicolas Viaud, Nathalie Granier, Stephanie Zerbib, Arnaud Dujardin, Cecile Bonnafous, Mathieu Blery, Carine Paturel, Benjamin Rossi, Anne Marie-Cardine, Armand Bensussan, Martine Bagot, Helene Sicard. Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4733. doi:10.1158/1538-7445.AM2013-4733
Mucocele of the Sphenoid Sinus
Authors: Lawrence C. McHenry, John F. Sullivan, Max J. Ryan, Daniel Miller
Journal: New England Journal of Medicine (1960)

THE case presented below is reported as an unusual occurrence, as an illustration of the difficulty in the diagnosis and management of destructive lesions in the region of the sphenoid sinus and to reemphasize the necessity of a pathological diagnosis before irradiation.A sinus mucocele arises from the retention and accumulation of mucoid secretions within the sinus, which eventually gives rise to expansion, thinning and distention or actual destruction of the wall. When the contents of the cavity are purulent, it is considered to be a suppurating mucocele or a pyocele.1 , 2 The sphenoid sinus, which may vary in capacity from . . .
Populations of cells exhibiting epithelial-mesenchymal transition (EMT) or stem cell characteristics can be propagated from a single inflammatory breast cancer (IBC) cell line based on culture conditions.
Authors: BG Debeb, CS Hall, W Xu, NT Ueno, JM Reuben, F Robertson, A Lucci, TA Buchholz, GN Hortobagyi, M Cristofanilli, WA Woodward
Journal: Cancer Research (2009)

Abstract Abstract #103 We have previously reported the isolation of a novel IBC cell line (MDA-IBC-1) from human pleural effusion fluid by passaging cells under 3-dimensional (3D) mammosphere (progenitor-promoting) conditions and isolating attached 2-dimensional (2D) cells from ultralow attachment plates. Mammosphere culture is serum-free and growth factor enriched. Serum-starving 2D cells leads to spontaneous formation of floating mammospheres with the same percentage of CD44+24- cells as 3D cultured mammospheres. 2D cells display distinct fibroblastic morphology. Here we report that passage in 2D (standard) or 3D (mammosphere) culture selects for different molecular phenotypes: EMT in 2D and stem/progenitor-like in 3D. 3D cells are generated from 2D cells for all experiments and are examined at second passage. RT-PCR reveals embryonic stem cell pluripotency factors Oct-4, Nanog, Sox-2 and Rex-1 are expressed in 3D but not 2D MDA-IBC-1 cells. MicroRNAs reported to be involved in self-renewal of breast cancer cells including Let-7a,b,c,d,e and f are decreased in 3D cultures (&amp;gt;5 fold decrease) compared to 2D. MiR16, 21, 125b and 200c are also markedly reduced in 3D vs. 2D cells. On the other hand, EMT proteins, N-cadherin, vimentin, and fibronectin are only expressed in 2D culture and higher expression of snail and slug is observed in 2D compared to 3D. Correspondingly, E-cadherin is absent from 2D cells. Moreover, Notch1, a putative stem cell signaling pathway protein that has been shown to promote EMT by snail induction is upregulated in 2D cells compared to 3D, and in response to radiation in both 2D and 3D. It has been reported in some systems that EMT promotion can induce stem cells. The data herein suggest the MDA-IBC-1 maintains pluripotent cells capable of both EMT and stem-like phenotypes. MDA-IBC-1 provides a unique model to examine the interaction between stem cells and EMT and to examine the mechanisms of resistance and proliferation of both cell types. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 103.
Abstract 4676: Survival of gastric cancer differs by ethnicity: A population-based experience from British Columbia, Canada
Authors: Morteza Bashash, T Greg Hislop, Amil Shah, Nhu Le, Angela Brooks-Wilson, Chris Bajdik
Journal: Cancer Research (2011)

Abstract Introduction: Prognostic factors can be classified into three broad groups: i) tumor-related, ii) host-related, and iii) environment-related (health care, treatment, lifestyle) factors. The current study was conducted to examine the effect of ethnicity as a host-related factor for survival of gastric cancer patients in British Columbia, Canada. Methods: Data were obtained from the population-based BC Cancer Registry for patients diagnosed with invasive gastric cancer between 1984 and 2006. The ethnicity of patients was estimated according to their names and categorized as Chinese, South Asian, Iranian or Other (more than 80% of “Other” are British and Western Europeans). Cox proportional hazards regression analysis was used to estimate the effect of ethnicity adjusted for patient sex and age, disease histology, tumor location, disease stage and treatment. Results: Results from this study indicate significantly different survival of gastric cancer patients depending on their ethnic group (p&amp;lt;0.01). When considered separately according to the presence or absence of metastatic disease, significant differences were only found for non-metastatic disease (p&amp;lt;0.01). Furthermore, the association between survival and ethnicity was only significant for patients with non-metastatic disease who received therapeutic surgery (p&amp;lt;0.01). In multivariate analyses adjusting for patient factors, disease factors and treatment, there was a significant difference among ethnic groups. Only Chinese had significantly longer survival compared to the Other ethnicities, but this survival advantage was only seen for non-metastatic disease (HR=0.78, 95% CI=0.64-0.95). Conclusion: The difference observed in patient survival is not likely to be due to healthcare disparities among minority groups, as all BC residents are covered for healthcare through the BC Medical Services Plan (MSP). Ethnicity may represent underlying genetic factors. Such factors could influence host-tumor interactions by altering the tumor's etiology and therefore its chance of spreading. Alternatively, genetic factors may determine response to treatments. Finally, ethnicity may represent non-genetic factors that affect survival. Differences in survival support the importance of ethnicity as a prognostic factor, and may provide clues for the future identification of genetic or lifestyle factors that underlie these observations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4676. doi:10.1158/1538-7445.AM2011-4676